Together, the findings suggest HIV prevention and treatment may be entering an era defined by long-acting options rather than daily pills. Nyaradzo Mgodi, a Zimbabwean clinical trials specialist and HIV prevention researcher, told SciDev.Net: “The findings represent a significant shift in both HIV prevention and HIV treatment. Expanding choice on preventionThat emphasis on choice is shared by African HIV researchers working on the frontline of HIV prevention. She argues that HIV prevention should offer the same flexibility as family planning, allowing people to choose products that fit different stages of their lives. Consequently, governments are increasingly integrating HIV prevention into primary healthcare systems, rebuilding supply chains and retraining healthcare workers.